Seizures are among the most common presentations of brain tumors. Several tumor types can cause seizures in varying rates; neuroglial tumors and the gliomas are the most common ones. Brain tumors are the second most common cause of focal intractable epilepsy in epilepsy surgery series, with the highest frequency being dysembryoplastic neuroepithelial tumors and gangliogliomas. Seizure management is an important part of the treatment of patients with brain tumors. This review discusses clinical features and management of seizures in patients with brain tumors, including, neuroglial tumors, gliomas, meningioma and metastases; with the help of recent literature data. Tumor-related seizures are focal seizures with or without secondary generalization. Seizures may occur either as initial symptom or during the course of the disease. Brain tumors related epilepsy tends to be resistant to antiepileptic drugs and treatment of tumor is main step also for the seizure treatment. Early surgery and extent of the tumor removal are important factors for achieving seizure freedom particularly in neuroglial tumors and low grade gliomas. During selection of the appropriate antiepileptic drug, the general approach to partial epilepsies can be followed. There are several factors influencing epileptogenesis in brain tumor-related epilepsy which also explains clinical heterogeneity of epilepsy among tumor types. Identification of molecular markers may guide future therapeutic approaches and further studies are needed to prove antitumor effects of different antiepileptic drugs.
Introduction
Seizures are among the most common presentations of brain tumors. The frequency of epilepsy in patients with brain tumors ranges from 30 to 100% depending on tumor type [1] . Although any type of tumor can cause a seizure, neuroglial tumors, and gliomas are the most common ones. Dysembryoplastic neuroepithelial tumors (DNETs), gangliogliomas (GGs), low-grade glial tumors, glioblastomas, metastases, leptomeningeal tumors and primary CNS lymphomas are associated with seizures in varying rates [1] . Tumor-related seizures are symptomatic by nature; they are focal with or without secondary generalization [2] . Semiologic characteristics depend on the localization of the tumor. The course of the clinical picture of epilepsy may differ according to the tumor type.
Seizures may occur either as an initial symptom, that leads to the diagnosis of the tumor (seen in about 30-50% of patients); or during the course of the disease (seen in 10-30% of patients) [1] .
The seizure risk is influenced by type and location of tumor and the number of the lesions [3] . Slow growing tumors, particularly DNETs and gangliogliomas, are particularly epileptogenic and associated with the highest risk for seizures [2, 4, 5] . High-grade tumors have relatively lower rates of seizures. The location of the tumor is also important, for instance, cortical tumors are associated with a higher risk of causing seizures. Additionally, frontal, temporal and parietal tumors are associated with a higher risk of causing epilepsy than occipital tumors [2] . Multiple lesions are associated with a higher risk compared to a solitary lesions [3] . Infratentorial tumors are rarely associated with epilepsy [1] .
The treatment of patients with brain tumors requires a multidisciplinary approach and clinical management varies according to the type of tumor. Brain tumors related epilepsy is usually refractory to medical treatment, and surgical or radiological treatment of the underlying tumor (when possible) is the mainstay of the treatment for the seizures [6] . Brain tumors are the second most common cause of focal intractable epilepsy in epilepsy surgery series, with the greatest proportion related to DNETs and GGs [4] .
In this paper, we will review the clinical features and management of seizures in patients with brain tumors.
Epidemiology and clinical characteristics

Neuroglial developmental tumors
DNETs and gangliogliomas compose a specific group of tumors since they are highly epileptogenic developmental lesions clinically characterized by early onset seizures [7] . Although the population prevalence of DNETs and GGs is not high, they are among the most common causes of intractable focal epilepsy [4, 7] . Seizures are usually the first and the only symptom of the patients with developmental tumors. The frequency of seizures reaches to almost 100% with DNETs and 80-90% with GGs [1] . They are benign tumors of neuroglial origin with a broad histopathological spectrum [7] . Eighty percent of DNETs are located in the temporal lobe, while extratemporal tumors constituting only about 20% of all DNETs. The most frequent extratemporal location is frontal [8] . GGs are also mostly located in the temporal lobes [7, 9, 10] . Both tumors have a benign course, therefore relapse and malignant progression are very rare [7] . They are classified in the group of 'low-grade epilepsy-associated tumors' (LEAT) [11] . LEATs are a specific group of tumors strongly associated with epilepsy. Their characteristics include a slow growth rate, early-onset drugresistant epilepsy, neocortical localization and temporal lobe predominance [5, 11] . There are various tumors in this group, however, the most common are DNETs and GGs. Following the developments in the molecular genetics, the WHO introduced a new classification based on a molecular genetic approach for some tumor entities [12] . However, LEAT's are still difficult to classify because they lack a clear clinicopathological and molecular genetic profile [11] . What is more, the MRI lesion may not match up with the epileptogenic zone, which may lead to a need for complex investigations with invasive EEG in some cases [7] . The mean age of onset of DNET is about 15 years [8] , of GGs it is 16-19 [10, 13] ; however, they may manifest also in young adults. The mean age at surgery is around 30 for both types of the tumors [8, 10] . Tumors can be associated with focal cortical dysplasia, however, the impact of focal cortical dysplasia on the epileptogenicity is still not clear. Focal seizures with loss of awareness are the most common seizure type associated with DNETs and GGs (seen in about 80% of cases) [8, 10] . Secondary generalized tonic-clonic seizures are seen in about 50% of patients. One exception to the preponderance of focal seizures is the histologically simple subtype of DNET, in which secondarily generalized seizures are most common [8] .
Low-grade gliomas (WHO grade II tumors)
Low-grade gliomas (astrocytoma, oligodendroglioma, oligoastrocytoma) are also associated with a high incidence of seizures. The overall proportion of patients with these tumors who develop seizures varies between 65-90% [9, [14] [15] [16] . A seizure is the most common presenting symptom, however, patients may also begin to develop seizures later in the course of the disease [1, 9] . These tumors are usually diagnosed between the ages 30-45 [15, 16] . An age of under 38 years and cortical involvement by these tumors have been identified as risk factors for seizures in patients with these tumors [16] . A location of the tumor close to functional areas makes it more likely to seizures to be present at diagnosis [15] . Contrary to neuroglial tumors, low-grade glial tumors more frequently involve extratemporal lobes with the highest frequency in frontal lobes. If the tumor involves the temporal lobe, it usually extends into the insula [9, [15] [16] [17] . Seizures are mostly secondarily generalized [16] . Seizures as the only presenting symptom of the tumor suggest a favorable prognosis [17, 18] . They may allow tumors to be diagnosed in at an earlier stage when the tumor is small enough and there is a higher chance of complete resection. Despite AEDs, 50% of the patients may be drug-resistant preoperatively. Insular location, prolonged time to diagnosis, and tumor within functional areas are factors associated with medically refractory seizures [15, 17] .
High-grade gliomas (WHO grade III-IV)
High-grade gliomas include anaplastic astrocytomas (AAs) and glioblastomas. Glioblastoma is the most common primary brain tumor in adults. The mean age at diagnosis is 60 years [19] . The overall proportion of patients with these tumors in which seizures are diagnosed has been reported as ranging from 40 to 62% [1, 19, 20] . Twenty-two percent of patients with these tumors had their first seizures after surgery [20] . Both focal and generalized seizures are observed during the course of glioblastoma. About 38% of patients have partial seizures, whereas 41% develop partial seizures with secondary generalization. Status epilepticus (SE) may also be observed in 12% of patients [19] . A frontal and temporal location are more frequent in glioblastoma and more commonly associated with seizures [20] . Another study reported status epilepticus (SE) in 12% of their study group consisting of patients with primary tumors. SE was seen most commonly in those with glioblastoma, the most frequent tumor location in those with SE was frontal or fronto-temporal [6] . Prophylactic AEDs do not reduce the incidence of epilepsy postoperatively, however, patients not receiving AEDs after surgery had a higher incidence of SE [20] .
Meningioma
Although most meningiomas are silent and benign; meningiomas may become symptomatic depending on the size and location of the tumor. Seizures are one of the most common manifestations of symptomatic meningiomas apart from headache and neurological deficits [21] . Surgical excision is the first choice of treatment for symptomatic intracranial meningiomas. The incidence of a preoperative seizure in patients with meningiomas is about 26-31% [21] [22] [23] . It is greater in older patients. The most common age at diagnosis of meningiomas subsequently treated with surgery is 50-60 years. The location of the tumor affects the seizure risk. Supratentorial meningiomas, mainly convexity and parasagittal, and peritumoral edema have been found to be associated with the greatest risk of seizures [22, 23] . Seizure freedom may be achieved in about 60-70% of meningioma patients with epilepsy [21, 23] . Risk factors for postoperative seizures include the presence of epilepsy before surgery, major surgical complications, epileptiform EEG activity, younger age and tumor progression. Therefore it has been suggested that EEG should be a part of the postoperative evaluation. This can contribute to a score based on the identified risk factors which may guide antiepileptic treatment postoperatively [21] . About 12-19% of meningioma patients without preoperative seizures may suffer from seizures after surgery [21] .
During the selection of an appropriate anticonvulsant drug for meningioma patients, general principles for focal epilepsy should be followed. In contrast to malignant tumors, drug interactions are rarely the case in meningiomas.
Metastases
Brain metastases develop about 20% of patients with systemic cancer [24] . Parenchymal and leptomeningeal metastases may lead to seizures. About 35% of patients with metastases have seizures, 20% being as the initial symptom [1, 25, 26] . In some cases where the seizure is the first symptom, cancer is diagnosed subsequently. The mean age of patients with metastases is about 70 years [25] . Although the commonest cause of seizures in patients with cancer is brain metastases; it should be born in mind that there may be other reasons for seizures associated with cancer such as electrolyte imbalances, chemotherapeutics, or paraneoplastic syndromes [24] . A seizure as the initial symptom is significantly more common in patients with primary CNS neoplasms than metastases. This may be explained by the less infiltrative growth pattern of brain metastases as well as their inability biochemically to modulate neuronal excitability [24] . Primary CNS lymphomas rarely cause seizures. They most commonly develop in the white matter and are usually not diagnosed because of an epileptic seizure [1, 24] .
Although patients with brain metastases may be prone to seizures, prophylactic AED treatment is not recommended in those who have not experienced seizures. However, in many centers, physicians may prescribes AED even in the absence of a seizure history [27] .
Pathology and molecular markers
The pathogenesis of tumor-related epilepsy is multifactorial and not fully understood [2, 28, 29] . Epileptogenesis by brain tumors is influenced by many factors including tumor histology, location, genetic factors, the integrity of the blood brain barrier and changes in the peritumoral environment such as neurotransmitter changes, ion concentrations and hypoxia [1, 2, 28, 29] . Greater levels of glutamate have been found in brain tumor samples of patients with epilepsy associated with tumors compared to those with nontumoral pathologies. Altered concentrations of GABA may also contribute to tumor-associated epilepsy [28] . Among the molecular genetic factors, the PI3K-mTOR pathway seems to be involved in epileptogenesis in neuroglial tumors in addition to its role in tumor growth [30] . The mechanisms may vary among tumor types. This may explain the difference in the frequency with which particular tumors are associated with seizures [2] . Several molecular markers have been identified in brain tumors in recent years. For instance, the clinical importance of isocitrate dehydrogenase 1/2 (IDH1/2) mutations, 1p/19q codeletion and MGMT promoter methylation for the patient's prognosis have been confirmed in many studies [31] . However, biological markers may also play a role in the development of seizures, and there are many studies looking for an association between biological markers and the risk of seizures in tumor-related epilepsies. IDH 1/2 mutations are common in diffuse low-grade gliomas and have been found to be associated with seizures as the initial symptom [30, 32] . Skardelly et al. also demonstrated that IDH mutation is a predictor of epileptogenicity and that different seizures rates within glioma subgroups are associated with differences in the prevalence of IDH mutations [26] . However, a recent large study did not confirm the relation between molecular markers (1p19q codeletion, p53 expression and isocitrate dehydrogenase 1 expression) and seizure in low-grade gliomas [15] . BRAF V600E mutations have been identified in glioneuronal tumors and their expression has been found to be associated with a worse postoperative seizure outcome [33] .
A number of molecular genetic markers has been identified as being associated with the seizure risk in patients with gliomas. The overexpression of nuclear protein Ki-67 was found to be a poor prognostic factor for seizure control in low-grade glioma patients [9, 16] . Another study suggested that high RINT1 expression may represent a risk factor for low-grade glioma (LGG) -related seizures andmay be associated with seizure outcomes [34] . Low expression of very large G-protein-coupled receptor-1 (VLGR) 1 [35] and dysregulation of miR-128 expression has also been found to be associated with epilepsy in low-grade gliomas [36] . A recent study of patients with anaplastic gliomas found low Ki-67 expression and EGFR amplification to be correlated with preoperative seizures [37] .
The role of EEG
All patients with a first seizure should undergo an MRI at the time of presentation which may show focal lesions such as tumors. Electroencephalography (EEG) also plays a role in the evaluation. EEG may help to localize the epileptogenic focus, to determine the patients who are at risk for recurrent seizures and guide decision regarding the need for antiepileptic drug therapy [25] .
Intraoperative EEG is performed in some centers. However, in their review, Englot et al. found no significant difference in terms of seizure outcome between patients with glioneuronal tumors and LGG with and without intraoperative EEG [38, 39] . However, they emphasize that electrocorticography may have been carried out in more severe cases of epilepsy which may have confounded results.
Invasive EEG recordings are used in about 10% of patients undergoing epilepsy surgery for tumor-related epilepsy. In extratemporal lobe epilepsy, invasive EEG is only needed when the lesion is close to eloquent cortex [40] . In this case it can help to confine the surgical resection by defining functional borders.
In the case of lesions in the non-dominant temporal lobe with a long duration of epilepsy characterized by frequent and disabling seizures, mesial structures should also be resected if they are involved or in close relation with the tumor. If the lesions is located in the dominant temporal lobe, if the mesial structures are not involved and properly functioning they should not be included in resection. Otherwise mesial structures should also be resected to optimise seizure outcome. In patients with temporal lobe tumorrelated epilepsy patients invasive EEG may only be carried out when the initial resection has failed to control seizures [40] .
Another study performed two stage surgery with intracranial EEG before tumor surgery to improve seizure outcomes in patients with primary brain tumors. They included 11 patients with glioneuronal, LGG and noninfiltrative tumors and found better seizure outcomes in patients with resection of the tumor and the seizure onset zone determined by intracranial EEG [41] . This approach may be preferred for some developmental tumors and LGG. Prospective investigations are needed to determine the role of intraoperative or invasive EEG on seizure outcomes of tumorrelated epilepsy.
A recent study on meningiomas attributed a significant role to the EEG because it found that epileptiform abnormalities on postoperative EEG were associated with an increased risk of postoperative seizures [21] .
Treatment of brain tumor-related epilepsy
In brain tumor-related epilepsy, control of epilepsy depends on the successful treatment of the tumor [24] . In addition to surgical resection and antiepileptic drugs, radiotherapy and chemotherapy may also play a role in the management of brain tumor-related epilepsy.
Surgical treatment and prognostic factors
Patients with glioneuronal tumors have long survivals and seizures tend to be refractory. Therefore seizure control is critical in the clinical management of glioneuronal tumors in terms of improving patients' quality of life [39] . This means that surgery is the treatment of choice for DNETs and GGs. The rates of seizure freedom following DNET surgery differ between studies but usually range from 68 to 83% [8, 39] . These rates are similar for GGs (70-85%) [10, 39, 42] . A shorter duration of epilepsy (less than 1 year) and gross total resection are the most important factors for achieving seizure freedom [39] . In addition, preoperative secondarily generalized seizures have been found to be associated with less favorable outcomes. No significant difference was found in outcomes between temporal versus extratemporal tumors, medically controlled versus refractory seizures [39] . Early surgery can produce seizure freedom and, considering the younger age of these patients, has additional benefits in terms of avoidance of side effects of the drugs during the development of younger brains. Because malignant progression is rare in glioneuronal tumors; there is no role of chemotherapy and radiotherapy. Invasive EEG recordings may be helpful in some cases.
Resection of the tumor improves seizure control also in LGG. Seizure freedom rates following LGG surgery range from 65 to 71% [16, 38] . Additionally, radiotherapy and chemotherapy alone or in combination have beneficial effects on seizure control [17, 18, 30] . The most important predictor of seizure freedom is gross total resection [15, 38] . Duration of seizures (less than 1 year), preoperative seizure control and control with antiepileptic medication are other influencing factors. Patients with simple partial seizures had a lower chance of achieving good seizure control [38] . Patients with secondarily generalized seizures and calcification on MRI, with gross total resection have better outcomes [16] . Following treatment of the tumor; a history of preoperative epilepsy and parietal and insular locations have been found to be associated with unfavorable seizure outcomes [15] .
Glioblastoma is an aggressive tumor. Standard treatment involves tumor resection followed by external beam radiation therapy (RT) with concomitant and adjuvant chemotherapy [43] . Seizure freedom rates following resection of glioblastoma are around 77% [18, 21] . Seizure recurrence is generally associated with progression of the glioblastoma, however, this association is not so clear for low-grade gliomas [18] .
Antiepileptic treatment
Antiepileptic treatment is an essential part of the seizure control. Prophylactic use of an antiepileptic drug in patients with brain tumors with no history of seizures is not recommended [44] . However, AEDs may be initiated following a first seizure related to a tumor. Seizures in brain tumors are partial onset seizures with or without secondary generalization. The general approach to partial epilepsies can be followed during decision of the appropriate drug. However, enzyme-inducing drugs such as carbamazepine and phenytoin should be avoided particularly in glioblastoma patients because of the risk of interaction with chemotherapeutics [19, 30] .
The potential antitumor effects of antiepileptic drugs have attracted considerable attention in recent years. Valproic acid (VPA) is most commonly discussed in this context. VPA has long been used for seizures. This has led to an accumulation of experience with this drug. Apart from providing seizure control, VPA has been shown to improve the survival of patients with glioblastoma in several studies and is therefore considered a good option as a first line treatment for epilepsy in patients with glioblastomas [19] . The risk of thrombocytopenia should be considered during VPA use in combination with chemotherapy [18] . However, a recent study which compared the effects of six different AEDs on survival in glioblastoma patients found no significant survival benefit either from treatment with AEDs for epilepsy in general nor from the use of any particular drug [43] . Some studies highlight the importance of the dosing schedule and target serum level of VPA while preferring it because of its potential additional effects on survival [45] .
Levetiracetam (LEV) is an efficient and well-tolerated AED [18] . An antitumor effect of LEV through O-6 methylguanine-DNA methyltransferase (MGMT) has been suggested. Therefore a beneficial effect of LEV on the survival of patients with glioblastoma who receive temozolomide-based chemotherapy has been hypothesized [46] .
Recently, several centers also reported their good experience with lacosamide [18, 30] .
Although there are several drug options, about 10-35% of patients remain refractory [18] .
In patients with no preoperative seizures who underwent surgery, there is no evidence to suggest that one should continue AEDs administered perioperatively to prevent acute symptomatic seizures. They should be discontinued after the first postoperative week [44] . However, clinical practices may differ among different centers related to physicians preferences [27] .
Patients with developmental tumors usually have a history of seizures preoperatively. Following successful surgery AED withdrawal can be considered. However, there is no consensus among different centers about the timing of AED withdrawal [47] , and physicians' practices vary in terms of AED withdrawal after successful epilepsy surgery [48] .
Conclusion
Seizures are among the common symptoms of brain tumors and seizure control is an important part of the clinical management of patients with brain tumors. Brain tumor-related epilepsy tends to be resistant to antiepileptic drugs and the treatment of tumor is an important means of achieving seizure control. There are several factors influencing epileptogenesis in brain tumor-related epilepsy which also explain the clinical heterogeneity of the epilepsies associated with different tumor types. Identification of molecular markers may guide future therapeutic approaches and further studies are needed to prove the possible antitumor effects of different antiepileptic drugs.
